Daniela Zackova
11PUBLICATIONS
46CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Mar 30, 2026
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Maria Agustina Perusini, Katia Pagnano, Carolina Pavlovsky
|Feb 27, 2025
Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib.Tomáš Horňák, Daniela Žáčková, Jiří Mayer
|Jan 28, 2025
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.Jiří Mayer, Petra Čičátková, Lenka Kováčová
|Sep 13, 2024
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.Petra Belohlavkova, Daniela Zackova, Hana Klamova
|Jul 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.Fabio Efficace, Francois-Xavier Mahon, Johan Richter
|Mar 13, 2024
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.Daniela Žáčková, Lukáš Semerád, Edgar Faber
Pageof 2
Frequent Collaborators
5 joint publications
Jiri Mayer
3 joint publications
Tomas Hornak
3 joint publications
Ivana Jeziskova
3 joint publications
Petra Belohlavkova
2 joint publications
Katerina Machova Polakova
2 joint publications
Marie Jarosova
2 joint publications
Markus Pfirrmann
2 joint publications
Susanne Saußele
2 joint publications
Henrik Hjorth-Hansen
2 joint publications
Johan Richter
